Shanghai Mabgeek Biotech.co.ltd

This study tests a new drug called MG-K10 in 180 teens aged 12-17 with moderate-to-severe eczema that hasn't responded well to creams. The drug is given as a shot every two weeks for a year. Researchers will check if it clears skin and reduces itching better than a placebo.

This phase 3 study tests an injectable drug called MG-K10 for people aged 12 and older with moderate-to-severe atopic dermatitis (eczema) that hasn't improved with creams. About 498 participants will receive either MG-K10 or a placebo to see if it safely reduces skin redness, itc…

This study tests a new medicine called MG-K10 for people with chronic hives (itchy welts) that don't get better with standard allergy pills. About 226 teens and adults will receive either the drug or a placebo injection every few weeks. The goal is to see if MG-K10 reduces itchin…